Aegerion Pharmaceuticals Announces Presentation at the Leerink Rare Disease Roundtable
24. September 2014 16:10 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 24, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...
Aegerion Pharmaceuticals Observes Familial Hypercholesterolemia Awareness Day
24. September 2014 09:00 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 24, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to...
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
09. September 2014 08:05 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 9, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
03. September 2014 16:05 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 3, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuticals Announces Resolution of Warning Letter for JUXTAPID(R) (lomitapide) Capsules
27. August 2014 07:00 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Aug. 27, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) today announced that it has received a closeout letter from the Office of Prescription Drug Promotion...
Aegerion Pharmaceuticals, Inc. Prices $300 Million Convertible Senior Notes Offering
12. August 2014 08:47 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Aug. 12, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) today announced the pricing of its offering of $300 million aggregate principal amount of 2.00%...
Aegerion Pharmaceuticals, Inc. Announces Intention to Offer $250 Million of Convertible Notes
11. August 2014 06:57 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Aug. 11, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) today announced its intention to offer, subject to market and other customary conditions, $250 million...
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
08. August 2014 08:35 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Aug. 8, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuticals Appoints Craig Fraser as Chief Operating Officer
30. Juli 2014 08:00 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., July 30, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...
Aegerion Pharmaceuticals Announces Second-Quarter 2014 Financial Results
29. Juli 2014 16:15 ET
|
Aegerion Pharmaceuticals, Inc.
- Company achieves $36.0 million in net product sales of JUXTAPID® with 34% growth in sales over first quarter
- Cash flow positive operations anticipated in the second...